Clinical Trial

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated March 26, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The efficacy and safety of Pazopanib combined with Palbociclib in the third line and above treatment of refractory solid tumors co amplified in the 11q13 region (FGF3/4/19/CCND1).
Trial Details
NCT Number NCT06895733
Lead Sponsor Tianjin Medical University Second Hospital
Conditions Solid Tumor, Adult, Next-generation Sequencing, Precision Medicine
Enrollment 65 participants
Start Date 2024-11-27
Primary Completion 2025-12-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-26